The Role of Blood Purification by Hemoadsorption as Adjunctive Treatment in Children With Septic Shock
NCT05401695 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2022-06-02
Summary
Sepsis is a major healthcare problem and leading cause of death in the pediatric population. Despite advances in supportive care of critically ill patients, sepsis remains an important cause of death worldwide in children. Overall, sepsis incidence peaked in early childhood. There were an estimated 20.3 million incident sepsis cases worldwide among children younger than 5 years. The Surviving Sepsis Campaign (SSC), which standardized the evidence-base approach to management of septic shock and other sepsis-associated organ dysfunction in children, was recently updated. Nevertheless, mortality and costs are still high.
Sepsis is characterized by a complex systemic inflammatory response to a microbial pathogen. A dysregulated host response to infection may result in life-threatening multi-organ dysfunction. Endotoxin, which is found in the outer membrane of Gram-negative bacteria, plays an important role in the pathogenesis of septic shock by producing proinflammatory cytokines. High levels of endotoxin and proinflammatory cytokines are associated with a high mortality rate.
Treatment strategies in sepsis and septic shock include early and adequate fluid resuscitation, vasopressors and inotropic support when indicated, early use of broad-spectrum antibiotics with source control, with close monitoring and organ support, if indicated. Other therapies such as immune-modulation and blood purification have been tried to improve outcomes in patients with sepsis and septic shock. Immunomodulation and blood purification techniques aim at restoring the balance of the immune response to infection, by removing the triggers for the response and the cytokines produced and thereby achieve immune homeostasis. Removing endotoxin and inflammatory cytokines would be an effective adjunctive approach in the management of severe sepsis.
Direct hemoadsorption (HA) is an extracorporeal technique utilized for blood purification. It involves the passage of blood through an adsorption cartridge, where solutes are removed by direct binding to the sorbent material. Over the years, new adsorption cartridge, with improved characteristics have been developed. Resin-directed hemoadsorption is associated with improved oxygenation, hemodynamic status and cardiac function. However, most studies include only adults, and little information is available regarding the clinical experience and efficacy of blood purification for pediatric septic shock.
This pilot study aimed to evaluate the overall clinical outcomes among children who received direct hemoadsorption as an adjunctive treatment for refractory septic shock with high severity scores, compared with outcomes among children admitted to the PICU who received standard treatment.
Conditions
- Septic Shock
- Multi Organ Failure
Interventions
- DEVICE
-
HA330 hemoadsorption technique
Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
Sponsors & Collaborators
-
Chulalongkorn University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Month
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-01
- Primary Completion
- 2022-04-30
- Completion
- 2022-04-30
Countries
- Thailand
Study Locations
More Related Trials
-
Cytokine Adsorption in Severe, Refractory Septic Shock
NCT04910893 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
NCT04057872 ·Status: COMPLETED ·Phase: PHASE1
-
Predictive Mini-bolus Fluid Responsiveness in Pediatric Septic Shock
NCT04027699 ·Status: COMPLETED ·Phase: NA
-
Cytokine Removal by CRRT in Pediatric Sepsis
NCT00537693 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of HA380 Hemoadsorption in Patients With Septic Shock
NCT04997421 ·Status: RECRUITING ·Phase: NA
-
Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis
NCT04533256 ·Status: COMPLETED
-
Early Resuscitation in Paediatric Sepsis Using Inotropes
NCT06478797 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of CA330 Hemoadsorption Device on IL-6 Removal in Septic Patients
NCT03847961 ·Status: UNKNOWN ·Phase: NA
-
Hemodynamic Impact of Cytosorb and CKRT in Children With Septic Shock
NCT05658588 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics and Pharmacodynamics of High Dose Ceftriaxone in Patients With Sepsis
NCT07245966 ·Status: COMPLETED
-
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study
NCT00732277 ·Status: COMPLETED ·Phase: PHASE2
-
Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock
NCT03948048 ·Status: RECRUITING
-
LifeFlow Sepsis Study
NCT07191054 ·Status: WITHDRAWN ·Phase: NA
-
Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
NCT00118664 ·Status: COMPLETED
-
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
NCT04013269 ·Status: UNKNOWN ·Phase: NA
-
The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis
NCT02413541 ·Status: COMPLETED ·Phase: NA
-
Electronic Application of a Severe Sepsis Screening Tool and Management Bundle
NCT01724463 ·Status: UNKNOWN
-
Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)
NCT02567305 ·Status: UNKNOWN
-
The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis
NCT06323226 ·Status: RECRUITING
-
AN69ST Verse PS in CBP in Septic Children
NCT05692011 ·Status: RECRUITING
-
Pharmacokinetics and Pharmacodynamics of Ceftazidime in Pediatric ICU Patients
NCT03133910 ·Status: UNKNOWN
-
Randomized Control Study in REsuscitation of SEpsis Trial
NCT07035509 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
NCT04102371 ·Status: COMPLETED ·Phase: PHASE3
-
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
NCT01947127 ·Status: COMPLETED